Total adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).
1 finding from 1 review
Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
1 finding from 1 review
Total adverse events · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in total adverse events compared with onabotulinumtoxinA 20U (moderate certainty).
1 finding from 1 review
Total adverse events · glabellar lines
Summary of Findings Table ‐ OnabotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Total adverse events · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
Total adverse events · glabellar lines
Summary of Findings Table ‐ IncobotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Total adverse events · glabellar lines
It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes total adverse events compared with onabotulinumtoxinA 24U (very low certainty).
1 finding from 1 review
Total adverse events · glabellar lines
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: severe adverse events (total) · children (aged 1 to 12 years) with CF and a newly isolated PA infection
Summary of findings: cycled showed no clear difference in adverse events: severe adverse events (total) compared with culture‐based antibiotic therapy (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
Adverse event data · women undergoing assisted reproduction
1 finding from 1 review
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
Adverse events ‐ total participants with adverse events · patients (mainly young male adults) with fractures of the middle third of the clavicle
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review